Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests
Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests
复制标题
DOI：
10.1097/fbp.0b013e328331b9bf
复制
发表时间：
2009-10-01
影响因子：
1.6
通讯作者：
Al-Rasheed, Nouf Mohammed
中科院分区：
文献类型：
--
作者：
Ahmed, Amany Ali Eissa;Al-Rasheed, Nawal Mohammed;Al-Rasheed, Nouf Mohammed
几项研究评估了噻唑烷二酮疗法作为治疗某些中枢神经系统疾病的药物，例如与神经退行性疾病相关的认知障碍。然而，支持过氧化体增殖物激活的受体-伽马激动剂在抑郁症中的直接作用的数据有限。因此，本研究的目的是利用小鼠悬尾实验和大鼠强迫游泳实验这两种对抗抑郁药作用敏感的模型来研究罗格列酮的抗抑郁药样作用。在尾部悬吊实验中，口服罗格列酮(8.5 mg/kg或17 mg/kg)5天可缩短小鼠不动时间。在强迫游泳实验中，口服罗格列酮(6 mg/kg或12 mg/kg)可减少小鼠的不动时间，增加爬升次数。在旷场测试中，这些效应并没有伴随着运动活动的任何变化。口服罗格列酮(6或12 mg/kg)可显著降低大鼠血浆皮质酮水平。GW9662显著抑制罗格列酮引起的不动时间缩短。综上所述，本研究提示罗格列酮在行为学模型中具有特异的抗抑郁药样活性，这种作用可能是通过降低血浆皮质酮水平来实现的。《行为药理学》20：635-642(C)2009沃尔特斯·克鲁沃健康垂直酒吧Lippincott Williams&Wilkins。
Several studies have evaluated thiazolidinedione therapy as medical treatments for some central nervous system disorders, such as cognitive deficits associated with neurodegenerative disorders. However, there is limited data to support a direct role for peroxisome proliferator-activated receptor-gamma agonists; in depression. Therefore, the aim of this study was to investigate antidepressant-like activity of rosiglitazone using the mouse tail suspension test and the rat forced swimming test, two models sensitive to the effects of antidepressants. In the tail suspension test, 5 days of treatment with rosiglitazone (8.5 or 17 mg/kg, orally) reduced immobility time. In the forced swimming test, rosiglitazone (6 or 12 mg/kg, orally) treatment decreased immobility time and increased climbing. These effects were not accompanied by any alteration in locomotor activity in the open field test. Rosiglitazone treatment (6 or 12 mg/kg, orally) significantly reduced plasma corticosterone levels in rats. GW9662 significantly inhibited the rosiglitazone-induced reduction in the duration of immobility.In summary, this study suggests that rosiglitazone possesses a specific antidepressant-like activity in behavioral models and that this effect may be mediated by reduction of plasma corticosterone level. Behavioural Pharmacology 20:635-642 (c) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.